A Phase 2 interventional study of Hu3F8 and GM-CSF in Neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing naxitamab in Neuroblastoma — 9 open to participants now, 12 under way, none of them phase 3. naxitamab · Neuroblastoma.
Among the 17 studies testing naxitamab in Neuroblastoma, this one is the 10th largest by enrollment, is one of 2 that started in 2017, is one of 11 in phase 2, and was the 4th registered.
676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.
Browse Neuroblastoma studies →9 of the 17 studies testing naxitamab in Neuroblastoma are open now, in 7 countries. Recruiting first, the newest first:
Giselle Sholler · Sites in United States
Ages 1–30
Shaare Zedek Medical Center · Sites in Israel
Ages 12 mo–21 yrs
Steven DuBois, MD · Sites in United States
Ages 1–30
Giselle Sholler · Sites in United States
Ages 1–21
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18 mo–19 yrs
By country, each count listing its studies:
naxitamab: first FDA approval 2020 (DANYELZA). What it is approved for, and how studies give it, is on its page →
Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 4 1
First in 2011; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is above the median of 33 across 508 interventional studies indexed under Neuroblastoma.
Median enrollment 62 across the 17 interventional studies. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 17 have an industry lead sponsor. The 8 most frequent:
Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.
Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.
51 studies in Neuroblastoma by Memorial Sloan Kettering Cancer Center: 5 open now, 10 under way, none of them phase 3. Of 40 finished, 13 (33%) have results posted.
Among the 51 studies in Neuroblastoma by Memorial Sloan Kettering Cancer Center, this one is the 14th largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2017, is one of 22 in phase 2, and was the 43rd registered.
Memorial Sloan Kettering Cancer Center’s Neuroblastoma studies by the year they started, since 1987.
5 of the studies testing naxitamab in Neuroblastoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01757626Memorial Sloan Kettering Cancer CenterCombination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma | 2026-12 |
| NCT06013618Sun Yat-sen UniversityClinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma | 2026-12-31 |
| NCT03189706Memorial Sloan Kettering Cancer CenterStudy of Chemoimmunotherapy for High-Risk Neuroblastoma | 2027-06 |
| NCT06047535SciClone PharmaceuticalsNaxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response. | 2027-06-15 |
| NCT07027748Steven DuBois, MDFeasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma | 2027-07-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 17 studies testing naxitamab in Neuroblastoma, from their registry updates:
Among Memorial Sloan Kettering Cancer Center’s 51 in Neuroblastoma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to test see the combined effects of the study drug called Humanized 3F8 (Hu3F8) when used with granulocyte-macrophage colony stimulating factor (GM-CSF). Hu3F8 plus GM-CSF could prevent your neuroblastoma from growing, but it could also cause side effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In this phase II single arm trial, patients with HR-NB in first CR or VGPR undergo consolidation by using hu3F8/GM-CSF x5 cycles and isotretinoin x6 cycles. Isotretinoin starts after cycle 2 of hu3F8/GM-CSF.
Biological: Hu3F8 · Drug: GM-CSF · Drug: Isotretinoin
Day 1: hu3F8 infused iv over \~30 to 90 minutes. Day 3: hu3F8 infused iv over \~30 to 90 minutes. Day 5: hu3F8 infused iv over \~30 to 90 minutes.
Days -4 to 0: GM-CSF 250 mcg/m2/day, subcutaneously. Days 1 to 5: GM-CSF 500 mcg/m2/day, subcutaneously.
Isotretinoin is administered at 160 mg/m2/d, divided into two doses, x14 days.
Relapse-free Survival (RFS)
Patients are considered a response failure under this protocol if progressive disease is evident before two years. Deaths from toxicity attributable to protocol treatment will be counted as events. Patients who withdraw or are lost to followup before two years will be considered as progressions.
Time frame: 5 years
| Milestone | Hu3F8/GM-CSF Plus Isotretinoin |
|---|---|
| Started | 59 |
| Completed | 59 |
| Not completed | 0 |
Patients are considered a response failure under this protocol if progressive disease is evident before two years. Deaths from toxicity attributable to protocol treatment will be counted as events. Patients who withdraw or are lost to followup before two years will be considered as progressions.
| months | Hu3F8/GM-CSF Plus Isotretinoin |
|---|---|
| Relapse-free Survival (RFS) | 10.2 (2.3 to 51.0) |
Collected over 5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Hu3F8/GM-CSF Plus Isotretinoin | 10/59 (16.9%) | 6/59 (10.2%) | 59/59 (100%) |
| Event | Hu3F8/GM-CSF Plus Isotretinoin |
|---|---|
| FeverGeneral disorders | 2/59 |
| Infections and Infestations - Other, specifyInfections and infestations | 2/59 |
| Sinus tachycardiaCardiac disorders | 2/59 |
| DehydrationMetabolism and nutrition disorders | 1/59 |
| Duodenal obstructionGastrointestinal disorders | 1/59 |
| HypertensionVascular disorders | 1/59 |
| HyponatremiaMetabolism and nutrition disorders | 1/59 |
| HypotensionVascular disorders | 1/59 |
| VomitingGastrointestinal disorders | 1/59 |
| Event | Hu3F8/GM-CSF Plus Isotretinoin |
|---|---|
| Lymphocyte count decreasedInvestigations | 33/59 |
| White blood cell decreasedInvestigations | 31/59 |
| Platelet count decreasedBlood and lymphatic system disorders | 28/59 |
| Neutrophil count decreasedInvestigations | 21/59 |
| Alanine aminotransferase increasedInvestigations | 19/59 |
| PainGeneral disorders | 9/59 |
| HypotensionVascular disorders | 7/59 |
| HyponatremiaMetabolism and nutrition disorders | 6/59 |
| Aspartate aminotransferase increasedInvestigations | 4/59 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 4/59 |
| Age, Continuous(years) | Hu3F8/GM-CSF Plus Isotretinoin |
|---|---|
| Median | 3.5 (0.46 to 17.8) |
| Sex: Female, Male(Participants) | Hu3F8/GM-CSF Plus Isotretinoin |
|---|---|
| Female | 27 |
| Male | 32 |
| Ethnicity (NIH/OMB)(Participants) | Hu3F8/GM-CSF Plus Isotretinoin |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 56 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | Hu3F8/GM-CSF Plus Isotretinoin |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 5 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 4 |
| White | 42 |
| More than one race | 0 |
| Unknown or Not Reported | 8 |
| Region of Enrollment(Participants) | Hu3F8/GM-CSF Plus Isotretinoin |
|---|---|
| United States | 59 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2017 to primary completion in Sep 2025, 104 months.
Results were first posted in Oct 2026, 1 year 1 month after primary completion.
Of 62 non-industry phase 2 interventional studies under Neuroblastoma, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 99. This study's 104 months is above that.
Counting every sponsor, half of 67 studies reached it within 74 months; a quarter within 52 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Naxitamab · Granulocyte-Macrophage Colony-Stimulating Factor
Memorial Sloan Kettering Cancer Center →